Latest Neulasta Stories
Believed to be the First Company to Have a Biosimilar Filing Accepted for Review of Amgen's Neulasta® TORONTO, Dec.
THOUSAND OAKS, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it will present data from several key NplateÂ® (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla.
THOUSAND OAKS, Calif., Oct. 5 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that results from several important studies from the Company's oncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.
New Vectibix(R) (Panitumumab) Combination Chemotherapy Data New Data Reinforce Importance of Infection Prevention in Chemotherapy Patients Oncology Pipeline Continues to Advance With New Data in Multiple Tumor Types THOUSAND OAKS, Calif., May 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced it will present new data from the Company's oncology portfolio of approved and investigational cancer products at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting...
- A gift; a largess; a gratuity; a present; a dole.